Identification of coagulation diagnostic biomarkers related to the severity of spinal cord injury

• Published in: International immunopharmacology 2024-08, Vol.137, p.112505, Article 112505
• Main Authors: Li, Jianfeng, Li, Junhong, Li, Xianlong, Wang, Wei, Ding, Yi, Zhou, Jiaxiang, Wang, Wentao, Xi, Yongming, Gou, Ruijie, Liu, Shaoyu, Zhou, Zhiyu, Gao, Manman
• Format: Article
• Language: English
• Subjects: Biomarkers; Blood; Coagulation; Immune cells; Regulation mechanism; Spinal cord injury
• ISSN: 1567-5769; 1878-1705; 1878-1705
• DOI: 10.1016/j.intimp.2024.112505

[Display omitted] •Identified coagulation diagnostic biomarkers associated with SCI and its various grades.•Identified blood immune changes associated with SCI and its different severity levels.•Predicted regulatory mechanisms and intervention drugs related to these diagnostic biomarkers. Blood always shows coagulation changes after spinal cord injury (SCI), and identifying these blood changes may be helpful for diagnosis and treatment of SCI. Nevertheless, studies to date on blood coagulation changes after SCI in humans are not comprehensive. Therefore, this study aims to identify blood coagulation diagnostic biomarkers and immune changes related to SCI and its severity levels. Human blood sequencing datasets were obtained from public databases. Differentially expressed coagulation-related genes were analyzed (DECRGs). Enrichment analysis and assessment of immune changes were conducted. Weighted gene co-expression network analysis, least absolute shrinkage and selection operator logistic regression were used to identify biomarkers. Validation for these biomarkers was performed. The correlation between biomarkers and immune cells was evaluated. Transcription factors, miRNA, lncRNA, and drugs that can regulate biomarkers were analyzed. DECRGs associated with SCI and its different grades were identified, showing enrichment in altered coagulation and immune-related signaling pathways. ADAM9, CD55, and STAT4 were identified as coagulation diagnostic biomarkers for SCI. IRF4 and PABPC4 were identified as coagulation diagnostic biomarkers for American Spinal Injury Association Impairment Scale (AIS) A grade of SCI. GP9 was designated as a diagnostic biomarker for AIS D grade of SCI. Immune changes in blood of SCI and its different grades were observed. Correlation between diagnostic biomarkers and immune cells were identified. Transcription factors, miRNA, lncRNA, and drugs that can regulate diagnostic biomarker expression were discovered. Therefore, detecting the expression of these putative diagnostic biomarkers and related immune changes may be helpful for predicting the severity of SCI. Uncovering potential regulatory mechanisms for biomarkers may be beneficial for further research.